Kazia closes oversubscribed offering to fund paxalisib’s clinical development

Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib. Paxalisib is being studied in various cancers and has received several regulatory designations from the FDA. Kazia’s other development programmes include EVT801, NDL2, and MSETC, with research underway across several solid tumour types. Credit: Zolnierek_photography / Shutterstock.com. Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at…

Source: Pharmaceutical Technology